Abstract:This Research Topic is part of the "Methods in Immunology" series, which highlights cuttingedge techniques and methods used to investigate fundamental questions in immunology research, with a focus on Alloimmunity and Transplantation (Figure 1) [1,2]. Alloimmunity is the immune response to alloantigens -immunogenic molecules from members of the same species, including blood group antigens and the highly polymorphic antigens of the major histocompatibility complex / human leukocyte antigens (MHC / HLA) (Figure 1A) [3][4][5].Alloantigens can be classified as major and minor mismatch antigens, which is distinguished from xenoantigens / xenoreactivity against different species, and autoantigens / autoimmunity against self-antigens [1, [3][4][5][6][7][8][9]. Alloantigens can trigger the formation of alloantibodies through alloantigen-primed B-cells and mature plasma cells (e.g. panel-reactive vs. donor-specific antibodies, PRA vs. DSA, respectively), as part of the humoral immune response, and the activation of effector T-lymphocytes, as part of the cellular immune response, with further amplification through secondary immune cell activation and infiltration [1,[3][4][5][6][7][8][9]. Both, humoral and cellular alloimmune responses can lead to acute and chronic graft rejection in solid organ transplantation (SOT), and graft failure or graft-versus-host disease (GVHD) in hematopoietic (stem) cell transplantation (HCT/HSCT) [10][11][12][13][14]. The most common SOT modalities include transplantation of kidneys (KTx), liver (LiTx), lungs (LuTx), heart (HTx), and vascularized composite allografts (VCA, e.g. hand, and face Tx) [1,2,15,16]. Successful allo-Tx requires precise "tissue matching" and optimal "IS protocols", to reduce the risk of immune rejection and to minimize IS toxicity [17]. Current advancements in alloimmunity and transplantation (Figure 1B) include next generation sequencing (NGS) for transcriptome analysis at both bulk or single cell levels (RNAseq and scRNAseq) [18,19], T-and B-cell receptor repertoire sequencing (TCRseq and BCRseq) [20][21][22], NGS analysis of donor-derived cell-free DNA (dd-cfDNA) [23][24][25][26], sophisticated in vitro and vivo models to study transplant rejection [14,27,28], but also novel concepts of transplantation (Tx), immunosuppression (IS), and patient care [17,29], including advanced therapy medicinal products and cell and gene therapies (ATMPs and CGTs) [1,12,17,[30][31][32][33][34][35]. Adjunct technologies include machine perfusion of donor organs, novel renal replacement therapies (RRTs), but also the exponentially increasing use of advanced bioinformatics, systems biology, and artificial intelligence, for optimal analysis and interpretation of increasingly complex / large data sets [1,[35][36][37][38][39][40][41][42]. recipients to assess the relevance of dd-cfDNA for detecting acute and chronic rejection, or infection one month post LuTx [23][24][25]. Total cfDNA was quantified with fluorimetry and digital PCR, cfDNA fragment size with BIABooster (Adelis), and dd-cfDNA with NGS (AlloSeq). While total cfDNA levels did not correlate with patient outcomes, higher dd-cfDNA were linked to graft injuries at d30 after LuTx (P=0.0004). A threshold of 1,72% dd-cfDNA effectively identified patients with healthy grafts, while higher levels of small dd-cfDNA indicated chronic injection or infection with 100% specificity.

Non‐invasive molecular biomarkers for monitoring solid organ transplantation: A comprehensive overview

Biomarkers for Renal Transplantation: Where Are We?

Molecular immune monitoring in kidney transplant rejection: a state-of-the-art review

Preliminary Investigation of the Biomarkers of Acute Renal Transplant Rejection Using Integrated Proteomics Studies, Gene Expression Omnibus Datasets, and RNA Sequencing.

A gentler approach to monitor for heart transplant rejection

Blood-based immunological monitoring after heart transplant. Current status and future prospects

Proteomics: Its Promise and Pitfalls in Shaping Precision Medicine in Solid Organ Transplantation

Biomarkers in Kidney Transplantation: A Rapidly Evolving Landscape

Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ Transplantation

Improving long-term kidney allograft survival by rethinking HLA compatibility: from molecular matching to non-HLA genes

Rejection markers in kidney transplantation: do new technologies help children?

Application of graft-derived cell-free DNA for solid organ transplantation

Editorial: Methods in alloimmunity and transplantation: 2023

Exosomes in transplantation: Role in allograft rejection, diagnostic biomarker, and therapeutic potential

Biomarkers from subcutaneous engineered tissues predict acute rejection of organ allografts

Prognostic Value of Endogenous and Exogenous Metabolites in Liver Transplantation

Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation

Nanotechnology-based Strategies for Molecular Imaging, Diagnosis, and Therapy of Organ Transplantation.

Developing Renal Allograft Surveillance Strategies – Urinary Biomarkers of Cellular Rejection

A Novel Next-Generation Sequencing Approach without Donor-Derived Material for Acute Rejection and Infection Monitoring in Solid Organ Transplantation

Donor liquid biopsy and outcomes in kidney transplantation